On January 16, the R&D and production headquarters of Nanjing Novlead Biotechnology Co., Ltd. and the medical industry platform of nitric oxide molecular technology were inaugurated in Jiangbei New Area Biomedical Valley.
At the scene, a figurative "wisdom tree" slowly displayed the word "NO (nitric oxide)" during the "watering" of the witnessing guests, representing the first national nitric oxide molecular technology medical industry platform in the Jiangbei new area. Through this innovative and unique way of opening, we hope to convey the company's willingness to be deeply rooted in Nanjing, an ancient capital of the Six Dynasties with many universities and a rich cultural heritage, and the Jiangbei New District Medical Valley, a place where many high-quality medical innovation enterprises have been developed. With the power of science and the spirit of innovation, and with the support of Jiangbei New District, the company will develop more innovative medical products with its unique nitric oxide molecular technology platform, showcase the Chinese style original innovative life science and technology enterprise, and bring this global innovative technology to a broader market, so that more patients can enjoy the benefits of original medical technology from China.
Dr. Wen Mao, CEO of Novlead, said: "Novlead has the world's leading nitric oxide generation and sustained release technology, relying on the company's original molecular technology platform, focusing on the development and production of innovative advanced medical devices, to develop innovative product systems for the significant unmet clinical needs that exist in the therapeutic areas of cardiopulmonary, respiratory and anti-infection ".
Novlead Bio has built a technology platform with electrochemical catalytic generation technology, molecular sustained-release control technology and gas composite sensing technology as the core, and has nitric oxide timely generation technology, nitric oxide sustained-release technology and nitric oxide sensor technology. Among them, the advantage of nitric oxide timely generation technology is the high purity of the generated gas, and the reaction rate of the generated gas can be controlled by electrochemical current, which is highly controllable.
Guiping Cao, COO of Novlead, introduced the current product items of the company. The first product on the market, "Portable NO Inhalation Therapy Device", has the advantages of miniaturization of the device, instant gas generation, and can be expanded to more hospital and home treatment scenarios. In addition, there are also wound healing gas topical therapies and exhaled gas NO detectors, which can cover 8 indications such as pulmonary hypertension, plateau pulmonary edema, diabetic foot ulcers, as well as pulmonary fibrosis and chronic obstructive pulmonary disease.
Chen Chanmei, member of the Party Working Committee and deputy director of the Management Committee of Jiangbei New Area of Nanjing, said in her speech that since its establishment, Jiangbei New Area has focused on the construction of "two cities and one center", and the output value of life and health industry represented by "Gene City" exceeded 100 billion last year. At present, the new area has formed an industrial chain including pharmaceutical R&D base - Biomedical Valley, medical, recreation, research and drug integration demonstration area - International Health City, and data platform - National Medical and Health Data (East) Center. As a practitioner of innovative medical devices, Novlead has been insisting on independent innovation. The new district will support the rapid rise of innovative enterprises with all resource elements and drive the synergistic development of the industrial chain.
With the inauguration of the R&D and production headquarters, Novlead will take the opportunity to produce more innovative medical products with its unique nitric oxide molecular technology platform and become a leading company focusing on high-end gas therapy and testing, based in China and with a global perspective, so that more patients can enjoy the benefits brought by China's original medical technology.
